Zhou Jing, Gong Chunling, Zhang Yu
Oral and Maxillofacial Surgery Department, Wuxi Stomatological Hospital 214000, Wuxi, PR China.
Oral and Maxillofacial Surgery Department, Wuxi Stomatological Hospital 214000, Wuxi, PR China.
J Stomatol Oral Maxillofac Surg. 2025 Jun;126(3S):102176. doi: 10.1016/j.jormas.2024.102176. Epub 2024 Nov 28.
Infantile hemangiomas (IH) represent the most prevalent vascular tumors in infants, often necessitating prompt medical intervention due to their potential for rapid growth and complications. This retrospective study aims to evaluate the efficacy of propranolol combined with Pingyangmycin in the treatment of IH and to investigate its correlation with vascular endothelial growth factor (VEGF) levels.
A prospective, observational study was conducted over 12 months, enrolling 120 IH patients. Patients received a combination therapy of propranolol and pingyangmycin for 3 to 6 months. Hemangioma Activity Score (HAS) and serum VEGF levels were assessed at baseline, 30th day, and 90th day post-treatment.
A total of 120 patients diagnosed with IH, including 68 males and 52 females with a mean age of 1.2 years, were enrolled in this study. The HAS at baseline was 8.5 ± 1.7, which significantly decreased to 4.2 ± 1.0 by Day 30 and further reduced to 2.1 ± 0.8 by Day 90 (P < 0.001 for both comparisons). Serum VEGF levels also showed a significant reduction from a baseline of 235.6 ± 42.1 pg/mL to 180.3 ± 34.7 pg/mL at Day 30 and to 122.8 ± 28.9 pg/mL at Day 90 (P = 0.02 and P = 0.01, respectively). The correlation analysis revealed a positive correlation between VEGF levels and HAS scores at all time points, with Pearson correlation coefficients ranging from -0.82 to -0.89 (P < 0.001). Adverse events were mild and transient, occurring in 15 % of patients, with the most common being mild hypoglycemia (8 %), transient bronchospasm (5 %), and gastrointestinal discomfort (2 %). All adverse events resolved with symptomatic treatment, and no patient discontinued therapy due to adverse reactions.
Propranolol treatment for infants with proliferative hemangiomas is significantly effective with minor adverse effects. The mechanism of action may be associated with the downregulation of serum VEGF levels.
婴儿血管瘤(IH)是婴儿中最常见的血管肿瘤,由于其有快速生长和引发并发症的可能,常常需要及时的医学干预。这项回顾性研究旨在评估普萘洛尔联合平阳霉素治疗IH的疗效,并研究其与血管内皮生长因子(VEGF)水平的相关性。
进行了一项为期12个月的前瞻性观察研究,纳入120例IH患者。患者接受普萘洛尔和平阳霉素联合治疗3至6个月。在治疗基线、治疗后第30天和第90天评估血管瘤活动评分(HAS)和血清VEGF水平。
本研究共纳入120例诊断为IH的患者,其中男性68例,女性52例,平均年龄1.2岁。基线时HAS为8.5±1.7,到第30天时显著降至4.2±1.0,到第90天时进一步降至2.1±0.8(两次比较P均<0.001)。血清VEGF水平也显著降低,从基线时的235.6±42.1 pg/mL降至第30天时的180.3±34.7 pg/mL,第90天时降至122.8±28.9 pg/mL(分别为P = 0.02和P = 0.01)。相关性分析显示,在所有时间点VEGF水平与HAS评分之间均呈正相关,Pearson相关系数范围为-0.82至-0.89(P<0.001)。不良事件轻微且短暂,15%的患者出现,最常见的是轻度低血糖(8%)、短暂性支气管痉挛(5%)和胃肠道不适(2%)。所有不良事件经对症治疗后均缓解,无患者因不良反应而停药。
普萘洛尔治疗增殖性血管瘤婴儿疗效显著,不良反应轻微。其作用机制可能与血清VEGF水平下调有关。